Le Lézard
Classified in: Health, Business
Subjects: PET, CXP

Primate CRO Alpha Genesis Continues Expansion Efforts With $3M Commitment


YEMASSEE, S.C., Dec. 12, 2018 /PRNewswire/ -- Primate contract research organization Alpha Genesis today announced the second phase of its multi-year expansion effort, committing an additional $3M over the next two years towards new construction and hiring to further enhance the Company's product and service offerings. This announcement follows a prior $2M initiative announced in 2016 which resulted in the Company building 50,000 square feet of new research space, and creating 30 full-time technical positions. The overall goal of these efforts is to position Alpha Genesis to effectively compete with Chinese expansion efforts in the primate bio-research industry. 

After experiencing several years of rapid growth, Alpha Genesis, which specializes in providing primate research products and services, plans to build a new and larger quarantine holding facility, and to enhance its service offerings by purchasing more specialized medical research equipment and hiring additional research staff. The Company will continue its outreach efforts to the European pharmaceutical community which continues to outsource much of its research needs to foreign entities, most notably to companies based in China and to a lesser extent to companies based in the United States. Alpha Genesis seeks to keep pace with Chinese research development efforts to provide a viable North American pre-clinical alternative. 

The Alpha Genesis Primate Research Center maintains a colony of 6,000 monkeys in South Carolina. Already, over 35% of its business focuses on in-house primate research, often for European companies, in the area of vaccine development and drug evaluation. Unlike most US-based primate CROs, Alpha Genesis raises most of its research animals domestically in order provide the highest standards of quality control, as well as to ensure a steady supply of research primates on known genetic origin. "My understanding is that restrictions in Europe have become quite significant in terms of how animals, particularly primates, must be housed and maintained, which has significantly driven up costs. The Chinese have seized on this opportunity by developing their own research resources and supply chain, and we are seeking to directly compete, but at a higher level, therein lies the reasoning and motivation for continued expansion of our facilities and staff expertise." says Westergaard. 

About AGI

Alpha Genesis is a leading life sciences company that provides primates and primate research services worldwide. With a mission to improve health and improve lives, Alpha Genesis delivers world-class solutions to the primate research community. To learn more about Alpha Genesis, visit www.alphagenesisinc.com and to learn more about the AGI Primate Research Center, visit www.primateresearch.com.

Media Inquiries: [email protected]

 

SOURCE Alpha Genesis


These press releases may also interest you

at 16:10
Medical Properties Trust, Inc. today announced it will host a conference call and webcast on Thursday, May 9, 2024 at 11:00 a.m. Eastern Time to discuss the company's first quarter 2024 financial results. A press release with first quarter 2024...

at 16:10
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by...

at 16:10
CareTrust REIT, Inc. announced today that it plans to release its first quarter 2024 financial results after the U.S. markets close on Thursday, May 2, 2024. Representatives of CareTrust REIT's management team will host a conference call to discuss...

at 16:10
AG Mortgage Investment Trust, Inc. (the "Company") announced today that it will release first quarter 2024 financial results prior to market open on Friday, May 3, 2024. The Company will host a conference call to discuss the results on Friday, May...

at 16:05
CN announced that the director nominees listed in the management information circular dated March 4, 2024 (the "Information Circular"), were elected as directors of CN. The detailed results of the vote for the election of directors held at CN's...

at 16:05
Civista Bancshares, Inc. ("Civista") announced today that the Board of Directors has approved a quarterly dividend of 16 cents per common share to shareholders of record May 7, 2024, payable May 22, 2024. ...



News published on and distributed by: